Use of a phospholipase A2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids

Abstract

The invention relates to the use of phospholipases, v.gr. sPLA2, as an active agent in the production of pharmaceutical and/or cosmetic compositions for the treatment of diseases caused by micro-organisms, the envelope or membrane of which comprises phospholipids, particularly glycerophospholipids. In particular, said invention relates to the use of sPLA2 from Crotalus durissus terrificus venom as a biocide component for the preparation of compositions for the treatment of viral infections, particularly acquired immunodeficiency states VIH-1 and VIH-2, bacterial and parasitic infections, such as infections caused by plasmodium and leishmania-type parasites.

Dependencies are inferred from the claim text.